Semaglutide: Large Trials, Narrow Questions Left Over

The short version

Semaglutide is a synthetic copy of a gut hormone called GLP-1, redesigned to survive in the body for about a week instead of a couple of minutes. GLP-1 is released after a meal; it tells the pancreas to release insulin when blood sugar is high, and it tells the brain that eating can stop. Semaglutide does both, more slowly and for far longer.

The trial record is unusually large. In adults with overweight or obesity and no diabetes, a weekly injection produced a mean body-weight change of -14.9% at 68 weeks against -2.4% on placebo ^[4]. In 17,604 adults with established cardiovascular disease, it cut the rate of heart attack, stroke or cardiovascular death by about a fifth ^[3]. In 3,533 people with type 2 diabetes and chronic kidney disease, it lowered the risk of major kidney events ^[2].

What those trials do not describe is any particular reader. They describe averages, in enrolled groups, over fixed periods.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human glucagon-like peptide-1, sharing roughly 94% sequence homology with the native hormone. Two substitutions in the backbone give it durability: at position 8, alanine is replaced by alpha-aminoisobutyric acid, which blocks cleavage by the enzyme dipeptidyl peptidase-4; at position 34, lysine is replaced by arginine.

The remaining lysine at position 26 carries a C18 fatty di-acid side chain attached through a glutamic-acid and ADO spacer. That lipid arm binds strongly and reversibly to albumin in the blood, which shields the peptide from kidney clearance and metabolism. It is the structural reason a once-weekly injection is possible at all — native GLP-1 is gone in about two minutes.

Its drug class is the GLP-1 receptor agonist, or incretin mimetic. It is approved in the United States for type 2 diabetes, for chronic weight management, for reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, for metabolic dysfunction-associated steatohepatitis. It is manufactured both as a once-weekly subcutaneous injection and as a once-daily oral tablet.

How it works

Semaglutide activates the GLP-1 receptor in several tissues at once. In the pancreas it potentiates glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon release from alpha cells — glucose-dependent meaning the insulin push only happens when blood sugar is already elevated. In the stomach it slows gastric emptying, which is both part of the satiety effect and the origin of most of its gastrointestinal side effects.

The weight effect, though, is largely central. The molecule reaches appetite circuits in the hypothalamic arcuate nucleus and the brainstem area postrema, where it activates the anorexigenic POMC and CART neurons and inhibits the orexigenic NPY and AgRP neurons. The result is reduced food intake and a shift in food preference, without a measured increase in energy expenditure. The same brainstem region that terminates a meal also generates nausea, which is why appetite suppression and queasiness arrive together rather than separately.

GLP-1 receptors also appear in cardiovascular and renal tissue, and the pleiotropic effects seen in the outcome trials are generally read against that distribution ^[2][3].

What the research shows

Weight, against placebo. In the STEP 1 randomised trial of 1,961 adults with overweight or obesity and without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, compared with -2.4% on placebo — a treatment difference of roughly 12.4 percentage points ^[4].

Weight, against a newer molecule. SURMOUNT-5, a head-to-head trial in 751 adults with obesity, compared semaglutide with tirzepatide over 72 weeks ^[1]. Tirzepatide produced greater mean weight loss: -20.2% against -13.7%, a gap of about 6.5 percentage points, P<0.001 ^[1]. The finding is precise and also narrow — it ranks two molecules on one endpoint in one enrolled population.

Cardiovascular events. The SELECT trial enrolled 17,604 adults with preexisting cardiovascular disease and a body-mass index of 27 or above, none of whom had diabetes ^[3]. Once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, with a hazard ratio of 0.80 (95% CI 0.72-0.90; P<0.001) — a 20% relative risk reduction ^[3].

Kidney outcomes. The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Once-weekly semaglutide 1.0 mg reduced major kidney-disease events — kidney failure, a decline in eGFR of 50% or more, or death from kidney or cardiovascular causes — with a hazard ratio of 0.76 (95% CI 0.66-0.88), a 24% lower risk than placebo ^[2].

Overall safety assessment. A dedicated safety review of trial and pharmacovigilance data concluded that semaglutide carries an overall favourable risk-benefit profile in type 2 diabetes. Adverse effects were predominantly mild-to-moderate transient gastrointestinal events, with nausea in roughly one-third of patients; biliary disease was increased; and pancreatic and thyroid-cancer signals were ones for which definitive conclusions could not be drawn, owing to low incidence rather than to demonstrated risk ^[5].

Reported effects, cautions & safety

People taking semaglutide describe a consistent cluster of effects in patient communities and review sites. The following is anecdotal, not clinical evidence: it is compiled from what people say, carries no dose information, and has none of the controls a trial provides.

The benefit reported most often is not weight loss itself but the quieting of what many call food noise — the constant background preoccupation with the next meal going silent, often within the first week or two. Alongside it, people report sharply reduced cravings for sugar and for fried or greasy food, sometimes to the point of mild aversion, and a corresponding drift toward lighter meals. Weight loss is described by the large majority, usually as steady over months and slower after the early period. Among people using it for type 2 diabetes, improved blood-sugar and A1C readings are a common theme. A recurring secondary observation, discussed widely in those communities, is a fading interest in alcohol.

On the adverse side, nausea dominates, mentioned by roughly a third of reviewers and escalating to vomiting in a subset; it tends to peak early and after each dose increase, and to ease within a week or two. Sulfurous burps, bloating, constipation and diarrhoea, acid reflux, tiredness in the day or two after an injection, headaches linked to low fluid intake, taste changes and food aversions, and mild injection-site reactions all appear regularly. A smaller group reports hair shedding and a gaunter face several months in, which people generally attribute to the speed of the weight loss rather than to the drug.

The cited cautions run parallel to that picture. Gastrointestinal intolerance during dose escalation is the dominant adverse effect in trials and the leading cause of discontinuation, and it is mechanistic rather than incidental — delayed gastric emptying is part of how the molecule works ^[5]. Biliary disease, including gallstones, is increased, an effect attributed largely to the rate and magnitude of weight loss ^[5]. The class carries a boxed warning for thyroid C-cell tumours derived from rodent studies at supratherapeutic exposures, with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 treated as a contraindication; human data have not established a clear increase in thyroid cancer, and the signal is unconfirmed rather than demonstrated ^[5]. Acute pancreatitis is a class warning, and treatment is conventionally stopped where pancreatitis is suspected ^[5]. In people with pre-existing diabetic retinopathy, monitoring is advised when blood glucose is corrected rapidly ^[5]. The approved labelling contraindicates use during pregnancy. The oral formulation depends on strict fasted administration, because its bioavailability is very low and administration errors reduce the absorbed dose substantially.

Where it sits on the open-question map

Semaglutide is the case where the volume of evidence makes the remaining gaps easier to see rather than harder.

Individual response is not in the data. Trial results are means. The 14.9% figure at 68 weeks ^[4] is an average across 1,961 people, and the distribution around it — who lost far more, who lost almost nothing, and why — is not something a mean reports.

Time horizons stop where follow-up stops. SELECT ran its participants for a defined period and reported a hazard ratio over that window ^[3]. What the same molecule does over decades is not a question any completed trial has answered.

Composition of weight lost. How much of the loss is fat and how much is lean tissue is an active question in the field. The sources listed on this desk measure weight, not body composition, so nothing here settles it.

What happens after stopping. Weight regain following discontinuation is discussed extensively in the literature; the reference list here does not include a trial that quantifies it, so no figure is quoted. The magnitude is unaddressed by this page rather than small.

Signals that are open rather than negative. The pancreatic and thyroid-cancer questions are explicitly unresolved because the events are rare, not because a study found them absent ^[5]. An unconfirmed signal is not a cleared one.

Compounded and non-pharmaceutical material. Every trial cited here used the manufactured product. Material of unverified identity, purity or concentration is outside that evidence base entirely, and no result on this page transfers to it.

Each of those is a question about a specific person, a specific history and a specific time horizon. That is the territory of a licensed clinician working from a full medical record, and it is precisely the territory a literature digest cannot enter.